Skip to main content

Advertisement

Table 2 The treatment and management of ECMO

From: Prognosis of patients with fulminant myocarditis managed by peripheral venoarterial extracorporeal membranous oxygenation support: a retrospective single-center study

  Survivors ( n= 13) Non-survivors ( n= 9) P value
Steroid therapy 7 (54%) 2 (22%) 0.15
IABP use 13 (100%) 8 (89%) 0.41
CHDF use 2 (15%) 3 (33%) 0.32
Total operating time of ECMO, h 181 ± 22 177 ± 31 0.15
Complications associated with ECMO
  Total 3 (23%) 8 (89%) 0.004
  Leg ischemia 0 (0%) 2 (22%) 0.16
  Stroke 0 (0%) 2 (22%) 0.16
  Bleeding 2 (15%) 6 (67%) 0.02
  Multiple organ failure 2 (15%) 6 (67%) 0.02
  1. Data are presented as the mean ± standard deviation or as the number of patients (%).
  2. IABP intra-aortic balloon pump, CHDF continuous hemodiafiltration.